Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system

Elsie Oommen, Sandi P B Tiwari, N. Udupa, Ravindra Kamath, P. Uma Devi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: To entrap methotrexate (MTX) complexed with β-Cyclodextrin (βCD) into niosomes, to characterise niosomes for different physicochemical properties and to investigate the potential of niosome entrapped MTX- β- cyclodextrin complex in tumour treatment. Methods: MTX- βCD complex was entrapped into niosomes by lipid layer hydration method. The entrapment efficiency of the complex within the niosomes was determined by separating the unentrapped drug using dialysis. The in vitro release studies of the drug from niosomes were conducted in phosphate buffered saline pH 7.4. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of one month. The niosome entrapped MTX - βCD complex was administered subcutaneously to C57BL/6J mice bearing melanoma B16F1 tumour at 10 mg kg-1 dose. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The niosomal entrapment efficiency was higher in the case of MTX - βCD complex (84%) than with the plain drug (67%). Comparison of the drug release profile revealed a relatively slow release pattern of the entrapped drug complex from the vesicles as compared to plain MTX encapsulated niosomes. Better stability on storage was also observed with the niosome entrapped complex. The complex entrapped niosomes produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: This study indicated that complexation of methotrexate with βCD could increase the entrapment of the drug in non ionic surfactant vesicles and could improve the anticancer activity. Additionally, the present approach could be a means to control the duration of drug action in situ in cases where the dissociation constants of cyclodextrin drug complexes can be tailored.

Original languageEnglish
Pages (from-to)279-284
Number of pages6
JournalIndian Journal of Pharmacology
Volume31
Issue number4
Publication statusPublished - 08-1999

Fingerprint

Cyclodextrins
Drug Delivery Systems
Methotrexate
Liposomes
Pharmaceutical Preparations
Neoplasms
Refrigeration
Drug and Narcotic Control
Growth
Inbred C57BL Mouse
Surface-Active Agents
Dialysis
Melanoma
Phosphates
Lipids
Temperature

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Oommen, E., Tiwari, S. P. B., Udupa, N., Kamath, R., & Devi, P. U. (1999). Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system. Indian Journal of Pharmacology, 31(4), 279-284.
Oommen, Elsie ; Tiwari, Sandi P B ; Udupa, N. ; Kamath, Ravindra ; Devi, P. Uma. / Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system. In: Indian Journal of Pharmacology. 1999 ; Vol. 31, No. 4. pp. 279-284.
@article{91a3f7ff693744339b7e63eea030bb40,
title = "Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system",
abstract = "Objectives: To entrap methotrexate (MTX) complexed with β-Cyclodextrin (βCD) into niosomes, to characterise niosomes for different physicochemical properties and to investigate the potential of niosome entrapped MTX- β- cyclodextrin complex in tumour treatment. Methods: MTX- βCD complex was entrapped into niosomes by lipid layer hydration method. The entrapment efficiency of the complex within the niosomes was determined by separating the unentrapped drug using dialysis. The in vitro release studies of the drug from niosomes were conducted in phosphate buffered saline pH 7.4. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of one month. The niosome entrapped MTX - βCD complex was administered subcutaneously to C57BL/6J mice bearing melanoma B16F1 tumour at 10 mg kg-1 dose. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The niosomal entrapment efficiency was higher in the case of MTX - βCD complex (84{\%}) than with the plain drug (67{\%}). Comparison of the drug release profile revealed a relatively slow release pattern of the entrapped drug complex from the vesicles as compared to plain MTX encapsulated niosomes. Better stability on storage was also observed with the niosome entrapped complex. The complex entrapped niosomes produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: This study indicated that complexation of methotrexate with βCD could increase the entrapment of the drug in non ionic surfactant vesicles and could improve the anticancer activity. Additionally, the present approach could be a means to control the duration of drug action in situ in cases where the dissociation constants of cyclodextrin drug complexes can be tailored.",
author = "Elsie Oommen and Tiwari, {Sandi P B} and N. Udupa and Ravindra Kamath and Devi, {P. Uma}",
year = "1999",
month = "8",
language = "English",
volume = "31",
pages = "279--284",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

Oommen, E, Tiwari, SPB, Udupa, N, Kamath, R & Devi, PU 1999, 'Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system', Indian Journal of Pharmacology, vol. 31, no. 4, pp. 279-284.

Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system. / Oommen, Elsie; Tiwari, Sandi P B; Udupa, N.; Kamath, Ravindra; Devi, P. Uma.

In: Indian Journal of Pharmacology, Vol. 31, No. 4, 08.1999, p. 279-284.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system

AU - Oommen, Elsie

AU - Tiwari, Sandi P B

AU - Udupa, N.

AU - Kamath, Ravindra

AU - Devi, P. Uma

PY - 1999/8

Y1 - 1999/8

N2 - Objectives: To entrap methotrexate (MTX) complexed with β-Cyclodextrin (βCD) into niosomes, to characterise niosomes for different physicochemical properties and to investigate the potential of niosome entrapped MTX- β- cyclodextrin complex in tumour treatment. Methods: MTX- βCD complex was entrapped into niosomes by lipid layer hydration method. The entrapment efficiency of the complex within the niosomes was determined by separating the unentrapped drug using dialysis. The in vitro release studies of the drug from niosomes were conducted in phosphate buffered saline pH 7.4. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of one month. The niosome entrapped MTX - βCD complex was administered subcutaneously to C57BL/6J mice bearing melanoma B16F1 tumour at 10 mg kg-1 dose. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The niosomal entrapment efficiency was higher in the case of MTX - βCD complex (84%) than with the plain drug (67%). Comparison of the drug release profile revealed a relatively slow release pattern of the entrapped drug complex from the vesicles as compared to plain MTX encapsulated niosomes. Better stability on storage was also observed with the niosome entrapped complex. The complex entrapped niosomes produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: This study indicated that complexation of methotrexate with βCD could increase the entrapment of the drug in non ionic surfactant vesicles and could improve the anticancer activity. Additionally, the present approach could be a means to control the duration of drug action in situ in cases where the dissociation constants of cyclodextrin drug complexes can be tailored.

AB - Objectives: To entrap methotrexate (MTX) complexed with β-Cyclodextrin (βCD) into niosomes, to characterise niosomes for different physicochemical properties and to investigate the potential of niosome entrapped MTX- β- cyclodextrin complex in tumour treatment. Methods: MTX- βCD complex was entrapped into niosomes by lipid layer hydration method. The entrapment efficiency of the complex within the niosomes was determined by separating the unentrapped drug using dialysis. The in vitro release studies of the drug from niosomes were conducted in phosphate buffered saline pH 7.4. The vesicle stability was assessed by storage at room temperature, 37°C and under refrigeration (4°C) for a period of one month. The niosome entrapped MTX - βCD complex was administered subcutaneously to C57BL/6J mice bearing melanoma B16F1 tumour at 10 mg kg-1 dose. The volume doubling time and growth delay of the tumour were taken as parameters to assess the antitumour efficacy. Results: The niosomal entrapment efficiency was higher in the case of MTX - βCD complex (84%) than with the plain drug (67%). Comparison of the drug release profile revealed a relatively slow release pattern of the entrapped drug complex from the vesicles as compared to plain MTX encapsulated niosomes. Better stability on storage was also observed with the niosome entrapped complex. The complex entrapped niosomes produced an improved anticancer activity as evident by enhanced volume doubling time and growth delay. Conclusion: This study indicated that complexation of methotrexate with βCD could increase the entrapment of the drug in non ionic surfactant vesicles and could improve the anticancer activity. Additionally, the present approach could be a means to control the duration of drug action in situ in cases where the dissociation constants of cyclodextrin drug complexes can be tailored.

UR - http://www.scopus.com/inward/record.url?scp=0032858744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032858744&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 279

EP - 284

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 4

ER -